Co-Encapsulation of Drugs for Topical Application—A Review

Ataide, Janaína Artem; Coco, Julia Cedran; Santos, Érica Mendes dos; Beraldo-de-Araújo, Viviane Lucia; Silva, Jéssica Ribeiro Alves; Castro, Karine Cappuccio de; Lopes, André Moreni; Filipczak, Nina; Yalamarty, Satya Siva Kishan; Torchilin, Vladimir P.; Mazzola, Priscila Gava

doi:10.3390/molecules28031449

Cited by 12 publications

(9 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in our study we have noticed the 2C5-modified nanopreparation to be safer than the DOX. Earlier studies have shown severe dermatological toxicities even with liposomal DOX treatment [32] however, in our 2C5 modified nanoparticle preparation we have observed none of these dermatological toxicities. Nonetheless, we observed such dermatological toxicities in the free drug (DOX) group alone.…”

Section: Discussioncontrasting

confidence: 77%

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model

Yalamarty,

Filipczak,

Pathrikar

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

A combination therapy with small interfering RNA (siRNA) and chemotherapeutic drug is proven to be effective in downregulating the cancer resistance proteins, such as P-glycoprotein (P-gp). These proteins are involved in multidrug resistance (MDR) of tumors. MDR lowers the efficacy of chemotherapy and even renders it ineffective. A possible strategy to counteract the resistance is by downregulating the resistance proteins using siRNA. A targeted formulation capable of delivering siRNA and chemotherapeutic drug will not only downregulate P-gp but also increase the concentration of the chemotherapeutic drug at the site of tumor thereby increasing the therapeutic effect and lowering the systemic exposure. In this study, monoclonal antibody 2C5-modified dendrimer-based micelles were used to co-deliver siRNA and doxorubicin (DOX) to the tumor site in both male and female xenograft mice model. The nucleosome-specific 2C5 antibody recognizes the cancer cells via the cell-surface bound nucleosomes. The ability of the 2C5-modified formulation in affecting the metastasis of highly aggressive triple negative breast cancer (MDA-MB-231) was assessed via wound healing assay where the 2C5-modified formulation halved the rate at which the cells were migrating. Further, the therapeutic efficacy of the formulation was assessed by measuring the tumor volume progression where the 2C5-modified nanoparticle group had a similar tumor volume to the free drug group at the end of the study, although a 50% increase in DOX concentrations in blood was observed after the last dose of nanoparticle. Despite a higher DOX concentration and residence time we did not observe any systemic toxicities in the nanoparticle groups. The free drug group on the other hand showed body weight reduction as well as the visible irritation around the injection spot. The treatment group with 2C5-modified micelles has shown to be safe at the current dose of DOX and siRNA.The ability of 2C5 antibody-functionalized nanoparticles in delivering cargo to the tumor site in vivo was evaluated for DOX using ex vivo imaging and siRNA by western blot study to evaluate the levels of P-gp. Furthermore, the siRNA mediated P-gp downregualtion was studied using western blotting assay. We observed a 29% reduction of P-gp levels in both males and females with respect to the control (BHG). We also conclude that the dose of DOX and siRNA should be further optimized to have a better efficacy in a metastatic tumor model, which will be the subject of our future studies.

show abstract

Section: Discussioncontrasting

confidence: 77%

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model

Yalamarty,

Filipczak,

Pathrikar

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In comparison to chemical penetration enhancers, nanoparticles have a number of benefits, including continuous medication release over an extended length of time and preservation of encapsulated compounds against chemical deterioration. The carrier must release the encapsulated medicine so that it may be absorbed via the skin layers and disease-related subcutaneous tissues for the best topical drug administration into the skin [ 101 ].…”

Section: Barrier In Skin and Nanoparticles (Nps) As Delivery Agentsmentioning

confidence: 99%

Nanoparticles assisted intra and transdermic delivery of antifungal ointment: an updated review

Tarannum,

Pooja,

Jakhar

et al. 2024

Discover Nano

View full text Add to dashboard Cite

This review paper highlights the trans-dermic delivery of nanoparticles (NPs) based antifungal ointments with the help of nanotechnology. It also describes the novel trans-dermal approach utilizing various nanoparticles which enables an efficient delivery to the target site. This current review gives an overview about past research and developments as well as the current nanoparticle-based ointments. This review also presents data regarding types, causes of infection, and different pathogens within their infection site. It also gives information about antifungal ointments with their activity and side effects of antifungal medicines. Additionally, this review also focuses on the future aspects of the topical administration of nanoparticle-based antifungal ointments. These nanoparticles can encapsulate multiple antifungal drugs as a combination therapy targeting different aspects of fungal infection. Nanoparticles can be designed in such a way that they can specifically target fungal cells and do not affect healthy cells. Nanoparticle based antifungal ointments exhibit outstanding potential to treat fungal diseases. As further research and advancements evolve in nanotechnology, we expect more development of nanoparticle-based antifungal formulations shortly. This paper discusses all the past and future applications, recent trends, and developments in the various field and also shows its bright prospective in the upcoming years. Graphical abstract

show abstract

“…On this basis, co-delivery of other chemotherapeutic drugs or natural active products also achieves synergistic therapeutic effect [ 53 ]. Chao and co-workers reported a mesoporous magnetite ferrite NP as an inorganic drug carrier, which can efficiently encapsulate hydrophobic drug (rifampin) and simultaneous co-load hydrophilic drug (isoniazide) [ 54 ].…”

Section: Co-delivery System In Medical Fieldmentioning

confidence: 99%

Recent Advances in Nanoparticle-Mediated Co-Delivery System: A Promising Strategy in Medical and Agricultural Field

Sun

Yin

et al. 2023

IJMS

View full text Add to dashboard Cite

Drug and gene delivery systems mediated by nanoparticles have been widely studied for life science in the past decade. The application of nano-delivery systems can dramatically improve the stability and delivery efficiency of carried ingredients, overcoming the defects of administration routes in cancer therapy, and possibly maintaining the sustainability of agricultural systems. However, delivery of a drug or gene alone sometimes cannot achieve a satisfactory effect. The nanoparticle-mediated co-delivery system can load multiple drugs and genes simultaneously, and improve the effectiveness of each component, thus amplifying efficacy and exhibiting synergistic effects in cancer therapy and pest management. The co-delivery system has been widely reported in the medical field, and studies on its application in the agricultural field have recently begun to emerge. In this progress report, we summarize recent progress in the preparation and application of drug and gene co-delivery systems and discuss the remaining challenges and future perspectives in the design and fabrication.

show abstract

Co-Encapsulation of Drugs for Topical Application—A Review

Cited by 12 publications

References 126 publications

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model

Nanoparticles assisted intra and transdermic delivery of antifungal ointment: an updated review

Recent Advances in Nanoparticle-Mediated Co-Delivery System: A Promising Strategy in Medical and Agricultural Field

Contact Info

Product

Resources

About